On Wednesday, China Finance Online Co. (ADR) (NASDAQ:JRJC)’s shares declined -4.93% to $5.98.
China Finance Online Co. (ADR) (JRJC) a leading web-based financial services company that provides Chinese retail investors with online access to securities and commodities trading, wealth administration products, investment advisory services, in addition to financial database and analytics services to institutional customers, declared that the company has launched the updated version 2.0 of its investment advisory service application Investment Masters (in Chinese “iTouGu”). The new version is accessible on the Company’s website and app stores for iOS and android.
The new features and functions in the updated version 2.0 comprise:
- Added a “What to Buy” sector, integrating advisors’ real-time portfolios and their market performance, in addition to recommendations for wealth administration products; and
- Improved application interface and functional flows for better user experience.
Through the brand new version of Investment Masters, investors can obtain private advices from online investment advisors, and also follow advisors’ stock holdings’ baskets to build their own optimal and suitable investment portfolio.
China Finance Online Co., Limited provides Web-based financial services in the Peoples Republic of China and Hong Kong. The company operates through three segments: Precious Metals Trading Services; Online Financial Information and Advisory Service, and Other Related Services; and Hong Kong Brokerage Services. It provides online access to securities and commodities trading services, wealth administration products, and securities investment advisory services to retail investors; and financial database and analytics to institutional investors, counting financial, research, academic, and regulatory institutions.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s shares dropped -4.85% to $2.16.
AVEO Pharmaceuticals, Inc. (AVEO) declared the relocation of its corporate headquarters to One Broadway in Cambridge, Massachusetts, effective recently. Compriseent with the Company’s aim of streamlining operations to align with its needs going forward, the new facility comprises of about 5,000 square feet of office space under flexible lease terms, with no laboratory or vivarium space. The new headquarters represents a reduction of about 90% in facilities from its preceding Cambridge location at 650 E. Kendall Square. AVEO also declared recently the unveiling of a new corporate logo.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development comprise Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has accomplished Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has accomplished a Phase I dose escalation study.
At the end of Wednesday’s trade, Protalix BioTherapeutics Inc. (NYSEMKT:PLX)‘s shares dipped -4.63% to $2.06.
Protalix BioTherapeutics Inc. (PLX) declared that Moshe Manor, the Company’s President and Chief Executive Officer, will present Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 1:00PM PM ET that will take place at the Grand Hyatt Hotel, New York, NY
Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its partner, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.
Tidewater Inc. (NYSE:TDW), ended its Wednesday’s trading session with -4.56% loss, and closed at $25.31.
Tidewater Inc. (TDW) declared that its Board of Directors declared on May 14, 2015, a quarterly cash dividend of $0.25 per share of common stock payable June 15, 2015, to shareholders of record on June 5, 2015.
Tidewater also declared recently that its Board of Directors has approved an extension of its current common stock repurchase program from its original expiration date of June 30, 2015 to June 30, 2016. If shares are purchased in open market or privately-negotiated transactions following this share repurchase program, the Company will use its accessible cash and/or borrowings under its revolving credit facility or other borrowings to fund any share repurchases. With this approved extension, the Company’s current repurchase program will continue in effect through June 30, 2016. Through May 13, 2015, a total of 2,841,976 of its common shares have been purchased by the Company under this program at a total cost of $100.0 million, or an average price paid per common share of $35.19. As of May 13, 2015, the Company had $100.0 million remaining authorized under this repurchase program accessible to repurchase shares. The Company will continue to evaluate share repurchase opportunities relative to other investment opportunities and in the context of current conditions in the credit and capital markets.
Tidewater Inc. provides offshore service vessels and marine support services through the operation of a fleet of marine service vessels to the offshore energy industry worldwide. It provides services in support of offshore exploration, field development, and production, counting towing of and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workover, and production activities; offshore construction, remotely operated vehicle (ROV) operations, and seismic support; and various specialized services, such as pipe and cable laying.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
